---
title: Targeted Therapy - Chemotherapy
type: content
phase: 1
status: complete
priority: high
tags: [targeted-therapy, tyrosine-kinase-inhibitors, monoclonal-antibodies, imatinib, trastuzumab, bevacizumab, EGFR-inhibitors, HER2]
created: 2025-11-08
last_modified: 2025-11-08
---

# Targeted Therapy - Chemotherapy

## Introduction

Targeted therapies are drugs designed to interfere with specific molecular targets involved in tumor growth and progression. Unlike traditional chemotherapy, these agents selectively target cancer cells while sparing normal cells, generally resulting in improved efficacy and reduced toxicity.

## Classification

### Small Molecule Tyrosine Kinase Inhibitors (TKIs)
- **Suffix**: "-nib"
- **Oral agents**
- Target intracellular kinase domains

### Monoclonal Antibodies (mAbs)
- **Suffix**: "-mab"
- **IV agents** (large proteins)
- Target extracellular receptors/ligands

### Other Targeted Agents
- Proteasome inhibitors, mTOR inhibitors, PARP inhibitors, etc.

---

## Tyrosine Kinase Inhibitors (TKIs)

### BCR-ABL Inhibitors (CML, ALL)

#### Imatinib (Gleevec)

**Mechanism**:
- **Inhibits BCR-ABL tyrosine kinase**
- BCR-ABL: Fusion protein in chronic myeloid leukemia (CML) - Philadelphia chromosome
- **Blocks ATP binding** → prevents phosphorylation → inhibits proliferation

**Clinical Uses**:
1. **Chronic myeloid leukemia (CML)** - first-line (chronic phase)
   - **Revolutionary**: Transformed CML from fatal to chronic disease
2. **Philadelphia chromosome-positive ALL** (Ph+ ALL)
3. **Gastrointestinal stromal tumors (GIST)** - c-KIT mutation

**Efficacy** (CML):
- **Complete cytogenetic response**: 80-90%
- **10-year survival**: ~85%

**Adverse Effects**:
- **Edema** (periorbital, peripheral) - common (20-70%)
- Nausea, diarrhea
- Muscle cramps, myalgias
- Rash
- **Myelosuppression** (less than traditional chemo)
- **Cardiotoxicity** (rare) - heart failure

**Drug Interactions**:
- **CYP3A4 substrate**:
  - Inhibitors (ketoconazole) → ↑levels
  - Inducers (rifampin, phenytoin) → ↓levels

**Resistance**:
- **BCR-ABL mutations** (T315I most common)
- Requires second/third-generation TKIs

**Clinical Pearls**:
- **First-line CML** (chronic phase)
- **Take with food** (↓GI side effects)
- **Monitor response** (cytogenetics, molecular BCR-ABL levels)

#### Dasatinib, Nilotinib (Second-Generation)

**Mechanism**: Inhibit BCR-ABL (more potent than imatinib, overcome some resistance)

**Clinical Uses**:
- **CML** (imatinib-resistant or intolerant, or first-line)
- **Ph+ ALL**

**Dasatinib Toxicity**:
- **Pleural effusions** (20-30%)
- **Pulmonary hypertension** (rare but serious)
- Myelosuppression

**Nilotinib Toxicity**:
- **QTc prolongation** (monitor ECG)
- **Hyperglycemia**, pancreatitis
- **Cardiovascular events** (arterial occlusive events)

#### Ponatinib (Third-Generation)

**Unique**: Active against **T315I mutation** (resistant to others)

**Clinical Uses**: **T315I-positive CML/ALL** or multiple TKI failures

**Toxicity**:
- **Black Box Warning**: **Arterial thrombosis** (MI, stroke, peripheral arterial disease)
- Hepatotoxicity, pancreatitis

---

### EGFR Inhibitors

**Target**: Epidermal growth factor receptor (EGFR/HER1)

#### Erlotinib, Gefitinib

**Mechanism**: **EGFR tyrosine kinase inhibitors** (reversible)

**Clinical Uses**:
1. **Non-small cell lung cancer (NSCLC)** - **EGFR mutation-positive**
   - **Activating mutations** (exon 19 deletion, L858R) predict response
   - **NOT for EGFR wild-type** (ineffective)
2. **Pancreatic cancer** (erlotinib with gemcitabine - modest benefit)

**Efficacy** (EGFR-mutant NSCLC):
- **Response rate**: 60-80%
- **PFS**: 9-13 months (vs 5-7 months chemo)

**Adverse Effects**:
- **Rash** (acneiform) - 50-80% (correlates with response)
- **Diarrhea** - common
- Interstitial lung disease (ILD) - rare, serious (1-5%)
- Hepatotoxicity

**Resistance**:
- **T790M mutation** (50% of acquired resistance)
- Requires third-generation EGFR TKI

**Clinical Pearls**:
- **Test EGFR mutation** before using (predictive biomarker)
- **First-line for EGFR-mutant NSCLC** (superior to chemo)
- **Rash correlates with efficacy** (often)

#### Osimertinib (Third-Generation)

**Unique**: Active against **T790M resistance mutation**

**Clinical Uses**:
- **EGFR-mutant NSCLC** (first-line or T790M-positive after progression)

**Advantages**:
- **CNS penetration** (brain metastases)
- **Better tolerability** (less rash, diarrhea than erlotinib/gefitinib)

**Toxicity**:
- QTc prolongation
- Interstitial lung disease (rare)

**Clinical Pearl**: **Preferred first-line EGFR TKI** (better efficacy, tolerability, CNS activity)

#### Afatinib

**Mechanism**: **Irreversible** EGFR inhibitor (also inhibits HER2)

**Clinical Uses**: EGFR-mutant NSCLC

**Toxicity**: Rash, diarrhea (more severe than erlotinib)

---

### ALK Inhibitors

**Target**: Anaplastic lymphoma kinase (ALK) - fusion protein in ~5% NSCLC

#### Crizotinib

**Mechanism**: **ALK tyrosine kinase inhibitor** (also inhibits ROS1, MET)

**Clinical Uses**:
1. **ALK-positive NSCLC** - first-line
2. **ROS1-positive NSCLC**

**Efficacy** (ALK+ NSCLC):
- **Response rate**: 60-70%
- **PFS**: 10 months

**Adverse Effects**:
- **Vision changes** (photopsia, blurred vision) - 60% (usually mild)
- **Edema**
- Nausea, diarrhea, vomiting
- **Hepatotoxicity** (monitor LFTs)
- **QTc prolongation**
- **Pneumonitis** (rare)

**Resistance**: ALK mutations → requires second-generation ALK inhibitors

**Clinical Pearls**:
- **Test ALK fusion** before using (FISH or IHC)
- **Vision changes common** (counsel patients)

#### Alectinib, Brigatinib, Lorlatinib (Second/Third-Generation)

**Advantages**:
- **Better CNS penetration** (brain metastases)
- **Overcome crizotinib resistance**
- **Superior efficacy** vs. crizotinib

**Clinical Pearl**: **Alectinib now preferred first-line** (superior PFS, CNS activity)

---

### BRAF Inhibitors

**Target**: BRAF V600E mutation (~50% melanomas, other cancers)

#### Vemurafenib, Dabrafenib

**Mechanism**: **BRAF serine/threonine kinase inhibitor**

**Clinical Uses**:
1. **BRAF V600E-mutant melanoma**
2. BRAF V600E-mutant other cancers (off-label)

**Efficacy** (melanoma):
- **Response rate**: 50-60%
- **Combined with MEK inhibitor** (see below): ↑efficacy, ↓toxicity

**Adverse Effects**:
- **Cutaneous squamous cell carcinoma, keratoacanthoma** (20%)
  - Paradoxical MAPK activation in BRAF wild-type cells
  - **↓Risk when combined with MEK inhibitor**
- **Photosensitivity** (severe)
- Arthralgia
- QTc prolongation
- Fever (dabrafenib)

**Clinical Pearls**:
- **Test BRAF V600E** before using
- **Always combine with MEK inhibitor** (↑efficacy, ↓SCC risk)

#### MEK Inhibitors (Trametinib, Cobimetinib)

**Mechanism**: Inhibit MEK (downstream of BRAF in MAPK pathway)

**Clinical Uses**: **Combined with BRAF inhibitor** (melanoma)

**Rationale**: Dual blockade MAPK pathway → ↑efficacy, ↓resistance, ↓SCC

**Toxicity**:
- Rash, diarrhea
- **Cardiomyopathy** (↓ejection fraction)
- **Retinal detachment** (rare)
- Hypertension

**Clinical Pearl**: **Combination therapy superior** to BRAF inhibitor alone

---

### HER2 Inhibitors

#### Lapatinib

**Mechanism**: Dual EGFR/HER2 tyrosine kinase inhibitor (reversible)

**Clinical Uses**:
1. **HER2-positive breast cancer** (with capecitabine)
2. HER2-positive metastatic breast cancer (trastuzumab-resistant)

**Adverse Effects**:
- Diarrhea (common)
- Rash
- **Hepatotoxicity** (monitor LFTs)
- Hand-foot syndrome
- Cardiac toxicity (less than trastuzumab)

**Clinical Pearl**: **Option for trastuzumab-resistant HER2+ breast cancer**

#### Tucatinib

**Mechanism**: Selective HER2 TKI

**Clinical Uses**: **HER2-positive breast cancer** (with trastuzumab + capecitabine)

**Advantage**: **CNS activity** (brain metastases)

---

### Multi-Kinase Inhibitors

#### Sunitinib, Sorafenib

**Mechanism**: Inhibit **multiple receptor tyrosine kinases** (VEGFR, PDGFR, c-KIT, others)

**Clinical Uses**:
1. **Renal cell carcinoma** (RCC) - first-line
2. **Hepatocellular carcinoma** (sorafenib)
3. **Gastrointestinal stromal tumors (GIST)** (sunitinib - imatinib-resistant)

**Adverse Effects**:
- **Hypertension** (VEGFR inhibition)
- **Hand-foot syndrome** (sorafenib)
- Fatigue, diarrhea
- **Hypothyroidism** (sunitinib)
- **Hepatotoxicity**
- Bleeding, thrombosis

**Clinical Pearl**: **Standard first-line RCC** (before immunotherapy era)

#### Pazopanib, Axitinib

**Similar**: Multi-kinase inhibitors for RCC

---

## Monoclonal Antibodies

### Anti-HER2

#### Trastuzumab (Herceptin)

**Mechanism**:
- **Monoclonal antibody against HER2 (ERBB2)**
- HER2 overexpressed in ~20% breast cancers
- Blocks HER2 signaling, mediates ADCC (antibody-dependent cellular cytotoxicity)

**Clinical Uses**:
1. **HER2-positive breast cancer** (adjuvant, metastatic)
2. **HER2-positive gastric cancer**

**Efficacy** (breast cancer):
- **↓Recurrence 50%** (adjuvant)
- **↑Survival** (metastatic)
- **Curative intent** when combined with chemo

**Adverse Effects**:

**Cardiotoxicity** (2-7%):
- **↓Ejection fraction**, heart failure
- **Reversible** (unlike anthracyclines)
- **Risk**: Prior anthracyclines, radiation, elderly
- **Monitor LVEF** (baseline, every 3 months)

**Infusion Reactions**:
- Fever, chills (first infusion)

**Pulmonary Toxicity** (Rare):
- Dyspnea, pneumonitis

**Contraindications**: Severe cardiac dysfunction, pregnancy (Category D)

**Clinical Pearls**:
- **Test HER2 status** (IHC, FISH) - predictive biomarker
- **Monitor cardiac function** (LVEF)
- **Combination with chemo** (more effective than alone)
- **Adjuvant therapy 1 year** (breast cancer)

#### Pertuzumab

**Mechanism**: Anti-HER2 mAb (different epitope than trastuzumab)

**Clinical Uses**: **HER2-positive breast cancer** (with trastuzumab + chemo)

**Rationale**: **Dual HER2 blockade** (trastuzumab + pertuzumab) ↑efficacy

**Toxicity**: Similar to trastuzumab (cardiotoxicity)

#### Ado-Trastuzumab Emtansine (T-DM1)

**Structure**: **Antibody-drug conjugate**
- Trastuzumab + emtansine (microtubule inhibitor)
- **Targeted delivery** of cytotoxic agent to HER2+ cells

**Clinical Uses**: **HER2-positive breast cancer** (metastatic, after trastuzumab)

**Advantages**: ↑Efficacy, ↓toxicity (targeted delivery)

**Toxicity**:
- Thrombocytopenia
- Hepatotoxicity
- Cardiotoxicity (less than trastuzumab alone)

---

### Anti-EGFR

#### Cetuximab

**Mechanism**: **Monoclonal antibody against EGFR** (blocks ligand binding)

**Clinical Uses**:
1. **Colorectal cancer** - **RAS wild-type only**
   - **NOT effective if KRAS/NRAS mutant**
2. **Head and neck cancer** (squamous cell)

**Predictive Biomarker**:
- **KRAS/NRAS mutation** → **resistance** (downstream activation)
- **Must test** before using (colorectal cancer)
- Only use if **RAS wild-type**

**Adverse Effects**:
- **Acneiform rash** (80-90%):
  - **Correlates with efficacy**
  - Manage with topicals, doxycycline
- **Hypomagnesemia** (renal Mg2+ wasting)
- **Infusion reactions** (can be severe)

**Clinical Pearl**: **Test RAS status** - only use if wild-type (colorectal)

#### Panitumumab

**Similar**: Fully human anti-EGFR mAb (vs. cetuximab - chimeric)

**Advantage**: Lower infusion reaction rate

---

### Anti-VEGF

#### Bevacizumab (Avastin)

**Mechanism**:
- **Monoclonal antibody against VEGF-A** (vascular endothelial growth factor)
- Blocks VEGF → **inhibits angiogenesis**
- **"Starves" tumor** of blood supply

**Clinical Uses** (Broad - many solid tumors):
1. **Colorectal cancer** (metastatic - with FOLFOX/FOLFIRI)
2. **Non-small cell lung cancer** (non-squamous)
3. **Renal cell carcinoma**
4. **Glioblastoma** (recurrent)
5. **Ovarian cancer**
6. **Cervical cancer**

**Adverse Effects**:

**Hemorrhage** (30%):
- **Life-threatening bleeding** (rare, <5%)
- **Contraindicated**: Recent hemoptysis, CNS metastases (bleeding risk)

**Hypertension** (30%):
- Monitor BP
- Treat with antihypertensives

**Proteinuria** (20%):
- Monitor urine protein
- **Discontinue if nephrotic syndrome**

**Thromboembolic Events** (10-15%):
- Arterial (MI, stroke) > venous (DVT/PE)

**GI Perforation** (1-2%):
- **Life-threatening**
- Abdominal pain → perforation
- Stop drug

**Impaired Wound Healing**:
- **Hold 4-6 weeks before/after surgery**
- VEGF required for wound healing

**PRES** (Posterior Reversible Encephalopathy Syndrome) (Rare):
- Headache, seizures, visual changes, hypertension

**Contraindications**:
- Recent surgery (<28 days)
- Recent hemoptysis
- Uncontrolled hypertension

**Clinical Pearls**:
- **Monitor BP, urine protein**
- **Hold before surgery** (4-6 weeks)
- **Avoid in squamous lung cancer** (hemoptysis risk)

---

### Anti-CD20

#### Rituximab

**Mechanism**: **Anti-CD20 monoclonal antibody**
- CD20: B-cell surface marker
- Mediates **B-cell depletion** (ADCC, complement)

**Clinical Uses**:
1. **Non-Hodgkin's lymphoma** (B-cell) - most common
2. **Chronic lymphocytic leukemia (CLL)**
3. **Autoimmune diseases**: Rheumatoid arthritis, ANCA vasculitis, ITP

**Efficacy** (lymphoma):
- **↑Survival** when added to chemo (R-CHOP vs. CHOP)

**Adverse Effects**:

**Infusion Reactions** (First Infusion, 50%):
- Fever, chills, hypotension, bronchospasm
- **Premedicate**: Acetaminophen, diphenhydramine, steroids
- **Slow infusion** initially

**B-cell Depletion**:
- **Hypogammaglobulinemia** (↑infection risk)
- Lasts months to years

**Hepatitis B Reactivation**:
- **Screen HBsAg, anti-HBc** before starting
- **Prophylactic antiviral** if positive
- Can be **fatal**

**Progressive Multifocal Leukoencephalopathy (PML)**:
- **JC virus** reactivation (rare but serious)
- **No treatment** (fatal)

**Tumor Lysis Syndrome** (TLS):
- Risk with large tumor burden
- **Hydration, allopurinol**

**Clinical Pearl**: **Standard for B-cell lymphomas** (combined with chemo)

---

### Other Targeted Agents

#### BTK Inhibitors (Ibrutinib, Acalabrutinib)

**Mechanism**: **Bruton's tyrosine kinase (BTK) inhibitor**

**Clinical Uses**:
1. **Chronic lymphocytic leukemia (CLL)** - now first-line (replaced fludarabine)
2. **Mantle cell lymphoma**
3. **Waldenström macroglobulinemia**

**Advantages**: **Oral**, **highly effective**, **avoid chemo toxicity**

**Toxicity**:
- **Atrial fibrillation** (10-15%)
- **Bleeding** (inhibits platelet function)
- Diarrhea
- Arthralgia

**Clinical Pearl**: **Revolutionized CLL treatment** (oral, effective, first-line)

#### Venetoclax

**Mechanism**: **BCL-2 inhibitor** (pro-apoptotic)

**Clinical Uses**: **CLL** (17p deletion or relapsed/refractory)

**Toxicity**: Tumor lysis syndrome (high risk - slow dose escalation)

---

## Clinical Pearls

1. **Targeted therapy** targets specific molecular alterations (precision medicine)
2. **Biomarker testing essential**: EGFR (NSCLC), ALK (NSCLC), BRAF V600E (melanoma), HER2 (breast), RAS (colorectal)
3. **Imatinib**: BCR-ABL inhibitor, first-line CML, revolutionized CML (chronic disease)
4. **EGFR TKIs** (erlotinib, osimertinib): EGFR-mutant NSCLC only, rash/diarrhea, osimertinib preferred
5. **BRAF + MEK inhibitors**: Combination superior (melanoma), test BRAF V600E
6. **Trastuzumab**: Anti-HER2, test HER2 status, monitor LVEF (cardiotoxicity)
7. **Cetuximab**: Anti-EGFR, RAS wild-type only (colorectal), acneiform rash
8. **Bevacizumab**: Anti-VEGF, hemorrhage/perforation/hypertension, hold before surgery
9. **Rituximab**: Anti-CD20, B-cell lymphomas, screen hepatitis B (reactivation risk)
10. **Ibrutinib**: BTK inhibitor, CLL first-line, atrial fibrillation risk

---

## Key Takeaways

1. **TKIs**: Small molecules, oral, target intracellular kinases ("-nib")
2. **mAbs**: Large proteins, IV, target extracellular receptors/ligands ("-mab")
3. **Biomarker-driven**: Test before using (EGFR, ALK, BRAF, HER2, RAS)
4. **Imatinib**: BCR-ABL inhibitor, CML chronic disease, edema common
5. **EGFR TKIs**: EGFR-mutant NSCLC, rash/diarrhea, osimertinib preferred (CNS, T790M)
6. **Trastuzumab**: Anti-HER2, breast cancer, cardiotoxicity (monitor LVEF)
7. **Bevacizumab**: Anti-VEGF, many cancers, hemorrhage/perforation/hypertension
8. **Rituximab**: Anti-CD20, B-cell lymphomas, infusion reactions, HBV reactivation
9. **Advantages**: Better tolerability than traditional chemo, precision medicine
10. **Resistance**: Common (mutations) - often requires salvage therapy

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
3. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition
4. NCCN Clinical Practice Guidelines in Oncology
5. Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001.
